Monocytes and γδ T Cells Control the Acute-Phase Response to Intravenous Zoledronate: Insights From a Phase IV Safety Trial

Joanne L Welton,1 Matt P Morgan,1 Salvador Martí,1 Michael D Stone,2 Bernhard Moser,1 Andrew K Sewell,1 Jane Turton,2 and Matthias Eberl1

1Cardiff Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
2Bone Research Unit, Cardiff University Academic Centre, Llandough Hospital, Penarth, United Kingdom

ABSTRACT
Aminobisphosphonates (NBPs) are used widely against excessive bone resorption in osteoporosis and Paget’s disease as well as in metastatic bone disease and multiple myeloma. Intravenous NBP administration often causes mild to severe acute-phase responses (APRs) that may require intervention with analgesics and antipyretics and lead to treatment noncompliance and nonadherence. We here undertook a phase IV safety trial in patients with osteoporosis to investigate the APR of otherwise healthy individuals to first-time intravenous treatment with the NBP zoledronate. This study provides unique insight into sterile acute inflammatory responses in vivo, in the absence of confounding factors such as infection or cancer. Our data show that both peripheral γδ T cells and monocytes become rapidly activated after treatment with zoledronate, which ultimately determines the clinical severity of the APR. Our study highlights a key role for IFN-γ in the zoledronate-induced APR and identifies pretreatment levels of monocytes and central/memory Vγ9/Vδ2 T cells as well as their responsiveness to zoledronate in vitro as predictive risk factors for the occurrence of subclinical and clinical symptoms. These findings have diagnostic and prognostic implications for patients with and without malignancy and are relevant for Vγ9/Vδ2 T-cell–based immunotherapy approaches. © 2013 American Society for Bone and Mineral Research.

KEY WORDS: AMINOBISPHOSPHONATES; γδ T CELLS; ACUTE-PHASE RESPONSE; OSTEOPOROSIS; IMMUNOTHERAPY

Introduction
There is increasing evidence that γδ T cells play a key role in orchestrating and regulating immune responses in humans and in animal models.10 Our own recent findings demonstrate that a rapid crosstalk of human γδ T cells and monocytes drives acute inflammatory responses, which may contribute to pathogen clearance and protective immunity but may also lead to tissue damage and poor clinical outcome.2,3 For reasons not yet understood, human γδ T cells differ fundamentally from those found in nonprimate species, and hence no small animal model replicates the complex interactions between γδ T cells and other immune and nonimmune cells in the human body.4,5

Nitrogen-containing bisphosphonates, or aminobisphosphonates (NBPs), are effective drugs against excessive bone resorption in osteoporosis, Paget’s disease, metastatic bone disease, and multiple myeloma. Despite their overall safety, NBP therapy is frequently associated with mild to severe inflammatory events, which may require intervention with analgesics and antipyretics and lead to treatment noncompliance and nonadherence.6,7 Treatment with intravenous NBPs such as pamidronate (Aredia; Novartis, Basel, Switzerland) and zoledronate (Aclasta/Zometa; Novartis) may cause systemic acute-phase responses (APRs) characterized by fever, pain, nausea, and fatigue in up to 50% of all patients within 48 hours after administration. These flu-like symptoms are typically transient, resolve spontaneously, and are accompanied by decreased lymphocyte counts and elevated levels of the pro-inflammatory cytokines IL-6, IFN-γ, and TNF-α.8-11 The APR upon intravenous treatment with NBPs is most severe in first-time treated patients, whereas subsequent further administration induces no APR.
symptoms at all or an APR with much milder outcome than at first exposure. For instance, in the HORIZON trial, net APR rates were 30%, 7%, and 3% after zoledronate (ZOL) infusions 1 to 3, respectively.(11,12) The immunological basis for this “tolerance” to repeated treatment with NBPs is not known.

Kunzmann and colleagues were the first to ascribe a role for γδ T cells in the NBP-induced APR.(13) Subsequent cell culture–based studies have elegantly demonstrated that NBPs are potent stimulators of Vγ9/Vδ2+ γδ T cells in vitro.(14–18) To act on Vγ9/Vδ2 T cells, NBPs depend on uptake by monocytes and other endocytically active cell types, in which they inhibit farnesyl pyrophosphate synthase (FPPS), a key enzyme in the biosynthesis of sterols, ubiquinones, and other isoprenoids via the mevalonate pathway. Preferential uptake by osteoclasts and subsequent inhibition of FPPS is the prime mechanism of action in the NBP-mediated prevention of bone resorption. However, FPPS inhibition in osteoclasts, monocytes, and other cells also leads to intracellular accumulation of upstream metabolites including dimethylallyl pyrophosphate (DMAPP), isopentenyl pyrophosphate (IPP), and an ATP conjugate of IPP (Apppl), which may function as “danger” signals and be sensed by Vγ9/Vδ2 T cells via a largely unknown mechanism.(19)

Despite the wealth of data from in vitro experiments, there has been a paucity of studies addressing the cellular events in vivo in NBP-treated patients. We here wished to study the physiological consequences of the human γδ T-cell interaction with monocytes in vivo and provide unique insight into purely γδ T-cell–mediated responses in the absence of confounding factors, by investigating the immune response of otherwise healthy individuals with osteoporosis to first-time administration of intravenous ZOL. During the revision process of the present study, Kalyan and colleagues reported the presence of circulating monocytes with increased forward scatter in ZOL-treated osteoporosis patients, yet did not characterize these cells further nor give any indication as to the time frame of this response.(20) Our own findings show that both γδ T cells and monocytes become rapidly activated after treatment with ZOL, thus providing proof-of-concept for the crosstalk of both cell types in vivo. Moreover, our study highlights a key role for IFN-γ in the NBP-induced APR and identifies pretreatment levels of monocytes and Vγ9/Vδ2 T cells as well as the proportion of central/memory TCM cells within the Vγ9/Vδ2 T-cell population and their in vitro responsiveness to ZOL as predictive risk factors.

Materials and Methods

Patients

This study was approved by the South East Wales Local Ethics Committee under reference number 10/WSE04/52, EudraCT number 2009-017369-47, and conducted according to the principles expressed in the Declaration of Helsinki and under local ethical guidelines. All patients provided written informed consent. The study cohort comprised 19 healthy nonsmoking adult females with postmenopausal osteoporosis and a bone density T-score of −2.5 or worse at either total spine, total hip, or neck of femur when measured by dual-energy X-ray absorptiometry (DXA). The mean age was 68 years (range 57 to 79 years).

All study participants were NBP naïve and attended outpatient appointments at Cardiff Royal Infirmary for first-time infusion of 5mg ZOL (Aclasta). Inclusion criteria included no contra-indications to treatment with intravenous NBPs; normal creatinine clearance levels of >35 mL/min; and normal vitamin D levels of 30 to 100 µg/L. Exclusion criteria included a body temperature >38.5°C at first visit; participation in another therapeutic trial within 20 days of consent; history of illness that might compromise participation such as drug or alcohol abuse; hypocalcaemia (<2.2 mmol/L corrected); and current use of oral steroids or other immunosuppressive agents. Vital signs such as resting pulse, resting blood pressure, and oral temperature and APR symptoms were recorded before treatment (day 0) and on days 1, 3, and 9 post infusion; cumulative APR scores (0 to 4) comprised one or several of the following symptoms for at least 24 hours after treatment: fatigue, muscle pain, headache, and/or joint pain. Blood parameters recorded included white blood cell (WBC) counts, erythrocyte sedimentation rates (ESR), and plasma levels of C-reactive protein (CRP) as markers of inflammation. From all patients, 15 mL of blood were drawn on each visit; PBMCs were isolated using Lymphoprep (Axis-Shield, Dundee, United Kingdom) and used directly for multicolor flow cytometric analyses or stored in liquid nitrogen for later stimulation assays.

Flow cytometry

Freshly isolated PBMCs were stained using monoclonal antibodies against CD3 (SK7 and UCHT1), CD4 (SK3), CD8 (HT8a), CD25 (M-A251), CD27 (M-T271), CD56 (B159), CD69 (FN50), and HLA-DR (L243) from BD Biosciences, Oxford, United Kingdom; Vγ9 (Immu360) and CD40 (MAB89) from Beckman Coulter, High Wycombe, United Kingdom; NK2G2D (1D11), CD14 (61D3), CD19 (SJ25C1), CD45RA (H100), and CD80 (2D10.4) from eBioscience, Hatfield, United Kingdom, together with appropriate isotype controls. Cells were acquired on an eight-color FACSCanto II (BD Biosciences, Oxford, UK) and analyzed with FlowJo 7.6 (TreeStar, Ashland, OR, USA). Leukocyte populations were identified based on their appearance in side scatter and forward scatter area/height, exclusion of live/dead staining (fixable Aqua; Invitrogen, Paisley, United Kingdom), and surface staining: CD3+ CD56− NK cells, CD3+ CD14+ monocytes, CD3+ CD19+ B cells, and CD3− T cells. T-cell subsets were identified as CD3+ CD4+ and CD8+ Vγ9+ helper T cells, CD3+ CD4+ CD8−Vγ9− cytotoxic T cells, CD3+ CD56+Vγ9+ NKT cells, and CD3+ Vγ9+ γδ T cells.

Plasma analysis

Plasma samples were collected before PBMC separation and stored at −80°C. At the end of the study, all samples were analyzed together on a SECTOR Imager 600 (Meso Scale Discovery, Rockville, MD, USA) for IL-1β, IL-2, IL-6, IL-10, IL-12p70, CXCL8, GM-CSF, IFN-γ, and TNF-α (Human Pro-Inflammatory 9-Plex Assay Ultra-Sensitive Kit; Meso Scale Discovery). In addition, CXCL10 and IL-17 were measured on a Dynex MRX II reader, using conventional ELISA kits (R&D Systems, Abingdon, United Kingdom).
Cell culture

The medium used was RPMI-1640 with 2 mM L-glutamine, 1% non-essential amino acids, 50 μg/ml penicillin/streptomycin, and 10% fetal calf serum (Invitrogen). Frozen PBMC samples were defrosted and cultured for 24 hours in medium or with 10 μM ZOL (Zometa). Activation of Vγ9/Vδ2 T cells was analyzed by flow cytometry using antibodies against CD3, Vγ9, and CD69; levels of IFN-γ were measured on a Dynex MRX II reader, using conventional ELISA kits (R&D Systems).

Statistical analysis

Differences between groups were analyzed using paired Student’s t tests for normally distributed data or Wilcoxon signed-rank matched pairs for nonparametric data using GraphPad Prism 4.03 software. Advanced statistical analyses were performed using SPSS 18.0. Differences between IFN-γ levels in groups with pretreatment frequencies of Vγ9/Vδ2 T cells above or below the mean were analyzed using independent t tests. Pearson’s correlations were used to assess any relationships between variables; nonparametric variables not passing the Shapiro-Wilk test were log-transformed as done for plasma levels of IFN-γ and TNF-α on day 1 and all IL-6 levels. Predictive biomarkers were assessed using linear regression; statistically significant (p < 0.05) variables from univariate analyses were included in multiple regression analyses based on backward selection. All statistical tests were two-tailed. Box-and-whisker plots depict minimum, 25th percentile, median, 75th percentile, and maximum values; arrows in Fig. 5 and Supplemental Figs. S1 and S2 depict significant correlations as assessed by Pearson’s correlations and/or regression analyses as specified in the figure legends. Asterisks indicate statistically significant differences to pretreatment values as indicated in the table and the figures: *p < 0.05; **p < 0.01; ***p < 0.001.

Results

First-time intravenous administration of ZOL causes APRs in osteoporosis patients

Upon first-time intravenous treatment with ZOL, the majority of patients experienced at least one APR symptom on day 1 (12/19) and day 3 (15/19) after treatment, two-thirds of which experienced at least two APR symptoms on day 1 (7/19) and day 3 (10/19). Nine days after treatment, 7/19 patients still had an APR score of ≥ 1. In line with the occurrence of APR symptoms, oral temperatures and pulse rates of patients were elevated on day 1 (Fig. 1). These changes were accompanied by a temporary drop in WBC (p < 0.05) and a concomitant rise in ESR (p < 0.01) on day 3 compared with baseline (not shown). Plasma levels of CRP were elevated on days 1 and 3 but returned to baseline by day 9 in most patients. Of note, all patients (19/19) showed considerable increases in CRP levels by day 3, and increases in CRP levels from baseline to days 1 and 3 correlated well with cumulative APR scores on days 1 and 3 (Table 1). These findings indicate not only that plasma CRP accurately reflected the severity of the APR but also that all patients showed an objective response to ZOL, albeit in many cases subclinically.

ZOL treatment induces systemic activation of γδ T cells

To investigate the immunological basis of the APRs in our patient cohort and to be able to identify biomarkers that may correlate with, or even predict, the increase in CRP levels or the extent of the clinical symptoms experienced, we measured a comprehensive range of humoral and cellular immune parameters of possible relevance in the APR. On the cellular level, we detected a temporary drop in peripheral Vγ9/Vδ2 T cells (measured as proportion of all circulating T cells) from 2.9 ± 0.8% (mean ± SEM) down to 2.1 ± 0.7% on day 3 (p < 0.05); these frequencies returned to baseline levels by day 9 (Fig. 2A). In contrast, proportions of CD4+ and CD8+ T cells were not affected (data not shown). This transient ~30% decrease in Vγ9/Vδ2 T cells was similar to the findings by Thompson and colleagues (18) in ZOL-treated osteoporosis patients and confirms the specificity of ZOL for Vγ9/Vδ2 T cells. Direct evidence for activation of Vγ9/Vδ2 T cells was obtained by measuring surface expression of CD25, CD69, HLA-DR, and NKG2D. Although CD25 levels remained low throughout the study period, CD69, HLA-DR, and NKG2D showed a significant upregulation on Vγ9/Vδ2 T cells after treatment (Fig. 2B). Moreover, the distribution of Vγ9/Vδ2 T-cell memory subsets changed significantly in that the proportion of CD27+CD45RA– central memory (TCM) cells dropped, whereas CD27–CD45RA+ effector/memory (TEMRA) cells and CD27+CD45RA+ terminally differentiated effector/memory (TEMRA) cells increased after treatment (Fig. 2C). These changes in the distribution of memory subsets were detectable for at least 9 days after treatment and indicated a longer-lasting systemic effect of ZOL on the Vγ9/Vδ2 T-cell compartment beyond the initial APR.
ZOL treatment induces systemic activation of monocytes

Vγ9/Vδ2 T cells only respond to NBPs after uptake by monocytes or other endocytically active cells. Because Vγ9/Vδ2 T cells stimulate monocyte survival and activation in vitro, we next examined the effects of ZOL administration on the circulating monocyte population in vivo. Of note, we detected a pronounced increase in the proportion of monocytes among total PBMCs on day 1 (Fig. 3). However, it is not clear whether this constituted a specific expansion of monocytes, as we detected a similar increase in B cells and a parallel drop in T cells (data not shown). This notwithstanding, there was a significant increase in the surface expression of CD14, CD40, CD80, and HLA-DR at 1 to 3 days after treatment, indicative of a considerable but transient activation of monocytes in vivo (Fig. 3) and evoking our earlier demonstration of an intimate crosstalk between γδ T cells and monocytes in vitro.\(^{(2)}\)

The ZOL-induced APR is characterized by elevated plasma cytokine levels

We next measured a range of soluble mediators in patient plasma, especially those that are associated with Vγ9/Vδ2 T-cell and/or monocyte responses. Among these, a sharp peak on day 1 was observed for IFN-γ, with an average increase of ~50-fold over baseline (Fig. 4). Less pronounced but nevertheless significant changes on day 1 were also detected for TNF-α and IL-6, in accordance with earlier studies.\(^{(8,18,22)}\) In addition, changes were seen for IL-2, IL-10, and GM-CSF (Fig. 4) as well as CXCL10 (data not shown). To our knowledge, the latter four factors have not been implicated in the APR to NBPs before. In contrast to these effects, plasma levels of IL-1β, IL-12p70, and CXCL8 (Fig. 4) as well as IL-17 (data not shown) did not change upon treatment with ZOL. These findings suggest that the APR to ZOL, evidenced by the occurrence of clinical symptoms and elevated CRP levels peaking at day 3, is preceded by a rapid and transient production of a distinct set of inflammatory mediators on day 1. Many of these factors were previously shown to play a role in the crosstalk between activated Vγ9/Vδ2 T cells and monocytes (IFN-γ, TNF-α, GM-CSF, IL-6, CXCL10).\(^{(2)}\)

IFN-γ takes center stage in the APR to ZOL

In an attempt to delineate the molecular and cellular events after systemic ZOL administration leading to the development of APR symptoms, we performed a detailed statistical analysis of a large range of humoral and cellular parameters, including the proportions of monocytes, B cells, NK cells, Vγ9/Vδ2 T cells, CD4 and CD8 T cells, and their expression of markers associated with activated cells (CD25, CD69, NKG2D), antigen-presenting

---

**Table 1. Correlations of CRP Values With APR Scores and Immune Biomarkers**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Day 1</th>
<th>Day 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>APR</td>
<td>0.510*</td>
<td>0.690*</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>0.332*</td>
<td>0.806**</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.452</td>
<td>0.245</td>
</tr>
<tr>
<td>%Vγ9+</td>
<td>0.595*</td>
<td>–0.135</td>
</tr>
<tr>
<td></td>
<td>–0.471</td>
<td>–0.154</td>
</tr>
<tr>
<td>Day 0</td>
<td>0.637**</td>
<td>0.325</td>
</tr>
<tr>
<td>Day 1</td>
<td>0.588*</td>
<td>0.706*</td>
</tr>
<tr>
<td>Day 3</td>
<td>0.400</td>
<td>0.464</td>
</tr>
<tr>
<td>Day 9</td>
<td>0.632**</td>
<td>0.365</td>
</tr>
</tbody>
</table>

Note: CRP increases above baseline were calculated by subtracting day 0 values. APR scores were expressed as cumulative symptoms on day 1 (score 0 to 4) or days 1 and 3 (score 0 to 8). Biomarkers analyzed before treatment (day 0) and on days 1, 3, and 9 after ZOL administration included plasma levels of IFN-γ and IL-6 (in pg/mL), and the frequency of Vγ9+ cells within the peripheral T-cell population. Values shown are Pearson’s coefficients (r). Numbers in italics indicate nonsignificant correlations.

* \(p < 0.05\).

** \(p < 0.01\).

---

**Fig. 2.** Activation of peripheral γδ T cells after ZOL treatment. Proportion of Vγ9+ T cells as percentage of all circulating CD3+ T cells (A); their surface expression of CD25, CD69, HLA-DR, and NKG2D (B); and the relative proportion of CD27+CD45RA- naive cells, CD27+CD45RA+ TCM cells, CD27-CD45RA+ TEM cells, and CD27-CD45RA- TEMRA cells amongst circulating Vγ9+CD3+ T cells (C). Differences were assessed using Student’s t-tests.
cells (CD40, CD80, HLA-DR), and/or memory cells (CD27, CD45RA). Amongst these parameters, we identified a positive correlation between IFN-γ levels on either day 1 or day 3 and the expression of CD69 on Vγ9/Vδ2 T cells on day 1 or day 3 (Supplemental Fig. S1A–D). CD69 expression on Vγ9/Vδ2 T cells on day 3 also correlated moderately with plasma TNF-α levels on day 3 (Supplemental Fig. S1D). Moreover, pretreatment frequencies of Vγ9/Vδ2 T cells ultimately determined IFN-γ levels on day 1 (Supplemental Fig. S1A), and pretreatment proportions of TCM cells within the Vγ9/Vδ2 T-cell population accurately predicted the levels of IFN-γ (Supplemental Fig. S1A) as well as TNF-α (Supplemental Fig. S1E) detected on day 1. No further post-treatment correlations were found between other cellular parameters and plasma cytokine/chemokine levels, except for a correlation between IFN-γ levels on day 1 and activation on NK cells on day 1 (Pearson’s coefficient, $r = 0.640^{**}$) or day 3 ($r = 0.766^{**}$), measured as CD69 expression on CD56+CD3− cells (not shown). Taken together, these findings are consistent with the view that activated Vγ9/Vδ2 T cells are the prime source of the elevated levels of IFN-γ in the circulation, and that activated Vγ9/Vδ2 T cells may also induce IFN-γ production by other cell types such as NK cells. A proposed model incorporating the described correlations is shown in Fig. 5. Of note, the depicted associations do not represent the result of a comprehensive path analysis or causal modeling but are derived from nonindependent regression models (individual Pearson’s correlations and separate multivariate analyses by backward selection as summarized in Table 1 and Supplemental Figs. S1 and S2) and should thus be interpreted with caution because of the potential inclusion of type I errors.

The occurrence of a specific monocyte–γδ T-cell crosstalk in ZOL-treated patients was supported by the demonstration that pretreatment frequencies of monocytes in PBMCs but no other pretreatment parameters correlated directly with the activation levels of Vγ9/Vδ2 T cells on day 1, day 3, and day 9, expressed as proportion of CD69+ cells (Supplemental Fig. S1F). Vice versa, there was a modest correlation between the frequency of Vγ9/Vδ2 T cells on day 1 and the activation status of monocytes on day 1 (Pearson’s coefficient, $r = 0.495^{*}$) and day 3 ($r = 0.557^{*}$), expressed as CD40 surface levels (not shown).

Of all humoral parameters measured, day 1 levels of IFN-γ (and IL-6) correlated with increased CRP levels on day 1 (Table 1) (Supplemental Fig. S2A, B). Using linear regression, only IFN-γ levels on day 1 were predictive of total APR symptoms (Supplemental Fig. S2A). No further correlations were found between other plasma cytokines/chemokines and CRP levels or APR symptoms. Taken together, these data emphasize a crucial and previously underestimated role for IFN-γ in the development of a ZOL-induced APR. Of note, CRP levels also correlated with pre- and post-treatment frequencies of Vγ9/Vδ2 T cells, indicating that the extent of the APR upon ZOL administration is influenced by the number of ZOL-responsive Vγ9/Vδ2 T cells (Table 1). In accordance with previous findings, high Vγ9/Vδ2 T-cell frequencies were indeed associated with an increased risk of APRs. Patients with pretreatment Vγ9/Vδ2 T-cell percentages greater than the median of 3% had significantly higher levels of IFN-γ on day 1, with a mean difference of 127 pg/mL (confidence interval 31 to 223 pg/mL; $p < 0.05$).
IFN-γ drives acute-phase response to zoledronic acid

The present phase IV safety trial is the most comprehensive study so far on the cellular immune response after intravenous NBP administration and provides evidence that both Vγ9/Vδ2 T cells and monocytes are involved in mediating the APR in vivo. Moreover, our study identifies a key role for IFN-γ in the NBP-induced APR, which may be of diagnostic and prognostic value and have implications for patient management. Given the proven efficacy of NBP in reducing the risk of fractures that are associated with high mortality, a simple test predicting the likelihood of a severe APR would allow the attending clinician to tailor medication to the individual and improve adherence to intravenous NBPs.

Our findings identify pretreatment frequencies of peripheral monocytes and Vγ9/Vδ2 T cells as well as the proportion of CD27+CD45RA+ TCM cells within the Vγ9/Vδ2 T-cell population and their responsiveness to ZOL in vitro as important predictors of the extent of pro-inflammatory cytokine production 24 hours after treatment. Incidentally, the cut-off value of >3% Vγ9/Vδ2 T cells identified by us above which patients showed considerably elevated IFN-γ levels at day 1 is in remarkable agreement with the failure of Rossini and colleagues to observe an APR in ZOL-treated osteoporosis patients who had pretreatment frequencies below 3% γδ T cells. These observations imply that the age and sex bias in peripheral Vγ9/Vδ2 T cells, which are higher in younger individuals and in women, is an important determinant of the APR incidence in different patient groups.

Our study also shows that ZOL administration caused a significant (albeit transient) drop in peripheral Vγ9/Vδ2 T cells and a longer-lasting reduction in the percentage of TCM cells among them. Earlier studies reported a similar drop in circulating Vγ9/Vδ2 T cells in osteoporosis patients after receiving a single dose of ZOL and a loss of TCM cells in cancer patients treated repeatedly with ZOL. As the loss of TCM cells occurring after a single administration of ZOL may last for at least a year, the qualitative and quantitative long-term effects of NBPs on the Vγ9/Vδ2 T-cell compartment appear to be the underlying basis for the general absence of adverse events in patients receiving repeat treatments. However, this correlation between the numbers of TCM cells in the circulation, the plasma levels of IFN-γ reached shortly after ZOL treatment, and the occurrence of APR symptoms is seemingly at odds with the present paradigm in Vγ9/Vδ2 T-cell biology. TCM cells are generally perceived as cells with high proliferative capacity but only modest cytokine production, as opposed to TEM and TEMRA cells, which proliferate poorly but produce copious amounts of cytokines upon restimulation. Our findings suggest that, in fact, activated TCM cells are the major source of the IFN-γ detected in the circulation after ZOL treatment, emphasizing the importance of in vivo studies in patients.

It is known from cell culture experiments that NBP-driven Vγ9/Vδ2 T-cell responses are sensitive to statins. By inhibiting 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway, statins lower the likelihood of abdominal aortic aneurysms that is exploited in the clinic to prevent cardiovascular diseases. Through the same mechanism, statins also counteract

![Diagram](https://example.com/diagram.png)
the NBP-induced intracellular accumulation of IPP, DMAPP, and AppII, and thus inhibit the activation of Vγ9/Vδ2 T cells in vitro. However, studies investigating the efficacy of statins in preventing the APR to intravenous NBPs have failed to demonstrate a clinical benefit, most likely because the plasma concentrations required for effective inhibition of IPP/DMAPP/AppII accumulation may not be reached pharmacologically. Our present findings suggest that interference with key players in the NBP-dependent Vγ9 T-cell-monocyte crosstalk such as IFN-γ might be an alternative therapeutic approach to manipulate the APR in patients at risk of severe reactions.

The present study has implications beyond the APR in osteoporosis patients. Recently, a transient drop in Vγ9/Vδ2 T-cell levels was interpreted as extravasation of activated cells into peripheral tissues, evoking similar findings in primate studies upon intravenous treatment with Vγ9/Vδ2 T-cell agonists. It is interesting to note that in primates activated Vγ9/Vδ2 T cells accumulate in the lung where they may confer some degree of protection against subsequent infection, which may be mirrored by reports showing that intravenous ZOL treatment has a largely unexplained beneficial effect in reducing pneumonia-related mortality.

Our findings also have implications for current attempts to utilize NBP-based treatment regimes for targeted therapy of cancer patients. Large cohort studies have shown that ZOL has beneficial effects beyond improving bone health and may prolong disease-free and/or overall survival in patients with breast cancer and multiple myeloma. The underlying reason for these direct antitumor properties is not clear but may involve Vγ9 T-cell-mediated effects. ZOL and other NBPs are, therefore, increasingly moving into the focus of novel immunotherapeutic approaches, especially in combination with low-dose IL-2 to boost the expansion and cytotoxicity of Vγ9/Vδ2 T cells. Previous studies identified possible “responders” and “nonresponders” based on the proliferative capacity of a patient’s Vγ9/Vδ2 T cells to NBP stimulation in vitro. However, it remains to be investigated whether the severity of the APR or levels of early immune biomarkers such as those described here correlate with long-term clinical outcomes after administration of NBPs with or without IL-2.

Taken together, our data are consistent with a model in which intravenously administered ZOL is taken up by monocytes, which thereby acquire the ability to “present” isoprenoid metabolites or related structures to Vγ9/Vδ2 T cells. Through mutual crosstalk, both monocytes and Vγ9/Vδ2 T cells undergo a series of activation and differentiation steps that ultimately determine the severity of the APR and replicate similar events taking place in acute infection. Although the effects on circulating monocytes appear to be only transient (be it because of rapid inactivation, extravasation and/or replenishment from the bone marrow), the Vγ9/Vδ2 T-cell pool shows longer-term changes in that TCM cells disappear and TEM cells and TEMRA cells become more prominent. Our findings imply that the gradual loss of TCM cells and their inability to produce IFN-γ is a major determinant of the reduced risk of experiencing APR symptoms in patients repeatedly treated with NBPs. Future studies will reveal whether the immediate response to first-time NBPs determines clinical outcome in patients with and without malignancy and whether it has diagnostic and/or prognostic value for Vγ9/Vδ2 T-cell-based immunotherapy approaches.

Disclosures

All authors state that they have no conflicts of interest.

Acknowledgments

We are grateful to all patients for their participation in this study and to our nurses Roz Broadbent, Cheryl Culley, Jacqui Dickens, and Sue Day for their help. We thank Sarah James for CRP measurements; Ann Kift-Morgan for technical assistance; Antony Wilkes for statistical advice; and Martin Davey, Francesco Dielli, Keith Thompson, and Massimo Massaia for the stimulating discussion. This research was in part supported by the Cardiff CR-UK Centre Development Fund and CR-UK project grant C28524/A9497.

Authors’ roles: Study design: AKS, JT, and ME. Study conduct and data collection: JLW and JT. Data analysis and interpretation: JLW, MPM, JT, and ME. Experimental methods: SMP. Study support and intellectual input: MDS and BM. Drafting manuscript: ME. Approving final version of manuscript: all authors. JT and ME take responsibility for the integrity of the data analysis.

References

11. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characteri-
zation of and risk factors for the acute-phase response after zole-


13. Kunzmann V, Bauer E, Wilhelm M. γδ T-cell stimulation by pami-


